A Study of LY3473329 in Healthy Japanese Participants
A Phase 1, Randomized, Investigator- and Participant-Blind, Placebo-Controlled Study of LY3473329 Multiple-Ascending Dosing in Healthy Japanese Participants
Sponsor: Eli Lilly and Company
Listed as NCT05038787, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Eli Lilly and Company, it has been updated 9 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE1
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE1
-
Oct 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .